Optimizing Commercial Success for Emerging Biopharmas
Key strategies to measure success
Achieving commercial success for a new drug has always been challenging, but the past 10 years have proven to be even more daunting. However, there are still valuable successes to analyze. Discover in this case study how IQVIA’s research on 505(b)(2) pathway drugs has revealed key insights that can help emerging biopharma (EBP) companies achieve critical success milestones including:
- Year-over-year profitability or net revenues surpassing commercial costs
- Cumulative break-even ratios and return on investments
- Speed to profitability or the time a product takes to break even
Download the case study.
